The Pfizer/Biontec vaccine proves effective in preventing young people from hospitalization | DW Arabic news | Breaking news and perspectives from around the world | DW


The Pfizer/Biontech vaccine has proven to be highly effective in preventing young teens from being hospitalized with Corona Virus, according to a new analysis from the US Centers for Disease Control and Prevention, Bloomberg News reported, today, Tuesday (October 19, 2021).

General Electric will require its approximately 56,000 employees in the United States to obtain a full vaccination against the Corona virus by December 8, and either obtain a medical or religious exemption by that date.

The United States will deny entry to foreign travelers who have recovered from COVID-19 and then received a single dose of a two-dose vaccine, a standard that France and the European Commission consider a full vaccination.

It is noteworthy that the European Medicines Agency, the body that approves the use of medicines in the European Union, announced yesterday, Monday, that it will review clinical trials on the effects of the Biontech / Pfizer vaccine against the emerging coronavirus (Covid-19) on children between the ages of 5 and 11 years.

It is noteworthy that the vaccine is currently licensed in the European Union only for those aged 12 years and over. The manufacturers of the Biontech/Pfizer vaccine disclosed data collected during trials in younger age groups.

Study data appears to show that the vaccine is well tolerated by children in this age group, who receive only one-third of the adult dose, and produces a stable immune response.



Please enter your comment!
Please enter your name here